Regence Spearheads Biosimilars Adoption, Reducing Annual Drug Spend by $37 Million

By |2022-11-16T12:38:32-07:00November 16th, 2022|Member News|0 Comments

Integrated adoption strategy drove successful conversion with 95 percent member utilization. SALT LAKE CITY, UT— Regence health plans are leading the nation in biosimilars utilization with 95 percent adoption, reducing specialty drug spend by $37 million annually. Biologics are specialty drugs that represent some of the most expensive treatments in the U.S., with annual [...]